|The promise and peril of chemical probes|
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
|Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors|
X Zhu, JL Kim, JR Newcomb, PE Rose, DR Stover, LM Toledo, H Zhao, ...
Structure 7 (6), 651-661, 1999
|The structure-based design of ATP-site directed protein kinases|
LM Toledo, NB Lydon, D Elbaum
Curr. Med. Chem 6, 775-805, 1999
|Molecular symmetry and the design of molecular solids: The oxalamide functionality as a persistent hydrogen bonding unit|
S Coe, JJ Kane, TL Nguyen, LM Toledo, E Wininger, FW Fowler, ...
Journal of the American Chemical Society 119 (1), 86-93, 1997
|Synthesis and self-assembly of pseudo-spherical homo-and heterodimeric capsules|
C Valdes, UP Spitz, LM Toledo, SW Kubik, J Rebek Jr
Journal of the American Chemical Society 117 (51), 12733-12745, 1995
D Armistead, J Bemis, L DiPietro, S Geuns-Meyer, G Habgood, J Kim, ...
US Patent App. 09/785,599, 2003
DM Armistead, JE Bemis, LV DiPietro, SD Geuns-Meyer, GJ Habgood, ...
US Patent 7,282,504, 2007
|Structures of staurosporine bound to CDK2 and cAPK–new tools for structure-based design of protein kinase inhibitors|
LM Toledo, NB Lydon
Structure 5 (12), 1551-1556, 1997
|Energetics of a low barrier hydrogen bond in nonpolar solvents|
Y Kato, LM Toledo, J Rebek
Journal of the American Chemical Society 118 (36), 8575-8579, 1996
|Discovery and structure–activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington’s disease|
ME Prime, OA Andersen, JJ Barker, MA Brooks, RKY Cheng, ...
Journal of medicinal chemistry 55 (3), 1021-1046, 2012
D Armistead, J Bemis, D Elbaum, G Habgood, P Novak, J Nunes, ...
US Patent App. 10/278,369, 2004
|Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening|
L Toledo-Sherman, E Deretey, JJ Slon-Usakiewicz, W Ng, JR Dai, ...
Journal of medicinal chemistry 48 (9), 3221-3230, 2005
|Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s disease|
LM Toledo-Sherman, ME Prime, L Mrzljak, MG Beconi, A Beresford, ...
Journal of medicinal chemistry 58 (3), 1159-1183, 2015
|Diels-Alder reaction of 2-cyano-1-azadienes. The effect of nitrogen substituents|
C Trione, LM Toledo, SD Kuduk, FW Fowler, DS Grierson
The Journal of Organic Chemistry 58 (8), 2075-2080, 1993
|Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery|
JJ Slon-Usakiewicz, JR Dai, W Ng, JE Foster, E Deretey, ...
Analytical chemistry 77 (5), 1268-1274, 2005
|High-throughput virtual screening for drug discovery in parallel.|
LM Toledo-Sherman, D Chen
Current opinion in drug discovery & development 5 (3), 414-421, 2002
DM Armistead, JE Bemis, JL Buchanan, LV DiPietro, D Elbaum, ...
US Patent 7,074,789, 2006
|Development of Strategies for the Preparation of Designed Solids. An Investigation of the 2-Amino-4 (1H)-pyrimidone Ring System for the Molecular Self-Assembly of Hydrogen …|
LM Toledo, K Musa, JW Lauher, FW Fowler
Chemistry of materials 7 (9), 1639-1647, 1995
|Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino] methyl]-1, 4-benzodioxan as orally active 5-lipoxygenase inhibitors|
Y Satoh, C Powers, LM Toledo, TJ Kowalski, PA Peters, EF Kimble
Journal of medicinal chemistry 38 (1), 68-75, 1995
|Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 …|
A Bresciani, A Missineo, M Gallo, M Cerretani, P Fezzardi, L Tomei, ...
Archives of biochemistry and biophysics 631, 31-41, 2017